

Translational Basic Research		
Basic research for latent infection – Imperial College London, BMGF/Wellcome Trust	Construction of a genome-scale metabolic model of <i>M. tuberculosis</i> – University of Surrey/ Biotechnology and Biological Sciences Research Council (BBSRC)	Identification of genes and biochemical pathways essential for survival in latent stage – Imperial College London, BMGF/ Wellcome Trust
Identification of compounds inhibiting pantothenate synthase (PanC) – NIH, NIAID, UCLA	Inhibitors of FtsZ – Stony Brook/Colorado State University, Southern Research Inst./ NIH	Inhibitors of menaquinone biosynthesis Stony Brook/Colorado State University/ NIH
Inhibitors of type-II NADH-menaquinone oxidoreductase – University of Pennsylvania		
Discovery		
Bacterial Topoisomerase Inhibitors GlaxoSmithKline, TB Alliance	Cell Wall Inhibitors Colorado State University, NIAID	Dihydrolipoamide Acyltransferase Inhibitors Cornell University, NIAID
Discovery for Latent Infection Imperial College London, BMGF/Wellcome Trust	Diphenyl ether based inhibitors of InhA Stony Brook/ NIH	Focused Screening GlaxoSmithKline, TB Alliance
Identification of compounds inhibiting the growth of <i>M. tuberculosis</i> – NIH, NIAID, TAACF	Identification of compounds with in vivo activity against <i>M. tuberculosis</i> in animal models – NIH, NIAID	InhA Inhibitors GlaxoSmithKline, TB Alliance
Malate Synthase Inhibitors – GlaxoSmithKline, Rockefeller University, Texas A&M	Multi-Functional Molecules Cumbre, TB Alliance	Natural Products Exploration BIOTEC, California State Univ., ITR, NIAID, TAACF, University of Auckland
Natural Products Exploration NERC Centre, University of Strathclyde, University of Illinois	Nitrofuranylamides NIAID, University of Tennessee	Nitroimidazole Analogs TB Alliance, University of Auckland
NM4TB Discovery Portfolio AstraZeneca, European Commission	Novartis Portfolio Novartis	Pleuromutilins GlaxoSmithKline, TB Alliance
Protease Inhibitors Medivir	Proteasome Inhibitors Cornell University	Promazine Analogs Salisbury University
Quinolones KRICT/ Yonsei University, TB Alliance	Riminophenazines – Institute of Materia Medica, BTTTRI, TB Alliance	Sanofi-Aventis Portfolio Sanofi-Aventis
Screening and Target Identification AstraZeneca	Thiolactomycin Analogs NIAID, NIH	
Preclinical		
Dipiperidine SQ-609 Sequella Inc.	Nitroimidazole Backup Compound Otsuka	Non-Fluorinated Quinolone TaiGen
TB Oxazolidinones Pfizer, Inc.	Synthase Inhibitor FAS20013 FASgen Inc.	Translocase I Inhibitors Sequella Inc., Sankyo
Clinical		
Diamine SQ-109 Sequella Inc.	Diarylquinoline TMC207 Tibotec Pharmaceuticals Limited	Gatifloxacin – OFLOTUB Consortium: Lupin, NIAID TBRU, Tuberculosis Research Centre, WHO TDR
Gatifloxacin DMID/NIAID/NIH, Case Western	Levofloxacin DMID/NIAID/NIH, Case Western	Linezolid DMID/NIAID/NIH, TBRU, Case Western
Metronidazole for Latent Infection Imperial College London, BMGF/Wellcome Trust	Moxifloxacin –Bayer Pharmaceuticals, CDC TBTC, Johns Hopkins University, NIAID TBRU, TB Alliance	Moxifloxacin DMID/NIAID/NIH, Case Western
Nitroimidazole PA-824 TB Alliance	Nitrodihydro-imidazoazole Derivative OPC-67683 – Otsuka Pharmaceutical Co.	Pyrrole LL-3858 (Sudoterb) Lupin Limited
SV07 Immune Modulator SciClone Pharmaceuticals		